Back then, it wasn't unreasonable to suspect that targeting an immune cell surface receptor with an engineered MAB would be playing with fire and likely pave a road to hell for patients receiving the novel treatment.

Precisely how Leronlimab avoids any harmful side effects while occupying one of these receptors is something I hope we learn much more about in the future.